ATE127696T1 - Wellenlängenspeziphisches, cytotoxisches mittel. - Google Patents

Wellenlängenspeziphisches, cytotoxisches mittel.

Info

Publication number
ATE127696T1
ATE127696T1 AT89307281T AT89307281T ATE127696T1 AT E127696 T1 ATE127696 T1 AT E127696T1 AT 89307281 T AT89307281 T AT 89307281T AT 89307281 T AT89307281 T AT 89307281T AT E127696 T1 ATE127696 T1 AT E127696T1
Authority
AT
Austria
Prior art keywords
tissues
cells
specific
wavelength
cytotoxic agent
Prior art date
Application number
AT89307281T
Other languages
English (en)
Inventor
Julia G Levy
David Dolphin
Jack K Chow
Ethan Sternberg
Original Assignee
Univ British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ British Columbia filed Critical Univ British Columbia
Application granted granted Critical
Publication of ATE127696T1 publication Critical patent/ATE127696T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0485—Porphyrins, texaphyrins wherein the nitrogen atoms forming the central ring system complex the radioactive metal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0036—Porphyrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
AT89307281T 1988-07-19 1989-07-19 Wellenlängenspeziphisches, cytotoxisches mittel. ATE127696T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/221,161 US4920143A (en) 1987-04-23 1988-07-19 Hydro-monobenzoporphyrin wavelength-specific cytotoxic agents

Publications (1)

Publication Number Publication Date
ATE127696T1 true ATE127696T1 (de) 1995-09-15

Family

ID=22826617

Family Applications (2)

Application Number Title Priority Date Filing Date
AT94115192T ATE209650T1 (de) 1988-07-19 1989-07-19 Wellenlängenspezifisches, cytotoxisches mittel
AT89307281T ATE127696T1 (de) 1988-07-19 1989-07-19 Wellenlängenspeziphisches, cytotoxisches mittel.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT94115192T ATE209650T1 (de) 1988-07-19 1989-07-19 Wellenlängenspezifisches, cytotoxisches mittel

Country Status (10)

Country Link
US (1) US4920143A (de)
EP (2) EP0352076B1 (de)
AT (2) ATE209650T1 (de)
AU (1) AU638675B2 (de)
CA (1) CA1339927C (de)
DE (3) DE68929351T2 (de)
ES (2) ES2169060T3 (de)
GR (1) GR3017426T3 (de)
LU (1) LU90718I2 (de)
NL (1) NL300037I2 (de)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5095030A (en) * 1987-01-20 1992-03-10 University Of British Columbia Wavelength-specific cytotoxic agents
US5198460A (en) * 1988-07-20 1993-03-30 Health Research Inc. Pyropheophorbides and their use in photodynamic therapy
US5002962A (en) * 1988-07-20 1991-03-26 Health Research, Inc. Photosensitizing agents
USRE38994E1 (en) 1988-07-20 2006-02-28 Health Research, Inc. Pyropheophorbides conjugates and their use in photodynamic therapy
USRE39094E1 (en) * 1988-07-20 2006-05-09 Health Research, Inc. Pyropheophorbides and their use in photodynamic therapy
AU641658B2 (en) * 1989-06-07 1993-09-30 University Of British Columbia, The Photosensitizing diels-alder porphyrin derivatives
US5087636A (en) * 1990-02-20 1992-02-11 University Of British Columbia Method to destroy malignant cells in mononuclear cell populations
US5214036A (en) * 1990-03-08 1993-05-25 University Of British Columbia Benzoporphyrin derivatives for photodynamic therapy
US5053423A (en) * 1990-03-22 1991-10-01 Quadra Logic Technologies Inc. Compositions for photodynamic therapy
US5120649A (en) * 1990-05-15 1992-06-09 New York Blood Center, Inc. Photodynamic inactivation of viruses in blood cell-containing compositions
GB9014307D0 (en) * 1990-06-27 1990-08-15 Scient Generics Ltd Method of treatment and compositions therefor
US5219878A (en) * 1990-10-05 1993-06-15 Queen's University Tetrapyrrole hydroxyalkylamide photochemotherapeutic agents
US5435307A (en) * 1991-03-29 1995-07-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Surface fluorescent monitor
US6890555B1 (en) 1992-02-05 2005-05-10 Qlt, Inc. Liposome compositions of porphyrin photosensitizers
CA2087902C (en) * 1992-02-05 2006-10-17 Narendra Raghunathji Desai Liposome compositions of porphyrin photosensitizers
US5330741A (en) * 1992-02-24 1994-07-19 The Regents Of The University Of California Long-wavelength water soluble chlorin photosensitizers useful for photodynamic therapy and diagnosis of tumors
CA2097280A1 (en) * 1992-06-01 1993-12-02 Sandor G. Vari Apparatus and method of use for a photosensitizer enhanced fluorescence based bipsy needle
JPH08505361A (ja) * 1992-08-17 1996-06-11 クアドラ・ロジック・テクノロジーズ・インコーポレーテッド 不所望細胞または組織を破壊しもしくはその成長を阻害する方法
US5798349A (en) 1994-03-14 1998-08-25 The General Hospital Corporation Use of green porphyrins to treat neovasculature in the eye
US6551618B2 (en) * 1994-03-15 2003-04-22 University Of Birmingham Compositions and methods for delivery of agents for neuronal regeneration and survival
ITFI940095A1 (it) * 1994-05-23 1995-11-23 Molteni & C Coniugati fotodinamici aventi proprieta' biocide
US5882328A (en) * 1995-01-13 1999-03-16 Qlt Phototherapeutics, Inc. Method to prevent transplant rejection
US5789433A (en) * 1995-01-17 1998-08-04 Quadra Logic Technologies, Inc. Green porphyrins as immunomodulators
US6107325A (en) * 1995-01-17 2000-08-22 Qlt Phototherapeutics, Inc. Green porphyrins as immunomodulators
US6096776A (en) * 1995-01-17 2000-08-01 Qlt Phototherapeutics, Inc. Green porphyrins as immunomodulators
DE19514088A1 (de) 1995-04-13 1996-10-17 Deutsches Krebsforsch Konjugat zur Behandlung von Entzünduns-, Infektions- und/oder Hauterkrankungen
US5707608A (en) * 1995-08-02 1998-01-13 Qlt Phototherapeutics, Inc. Methods of making liposomes containing hydro-monobenzoporphyrin photosensitizer
WO1997026885A1 (en) * 1996-01-23 1997-07-31 The General Hospital Corporation Doing Business As Massachusetts General Hospital Benzophenothiazine and benzoporphyrin dye combination photodynamic therapy of tumors
WO1999013943A1 (en) 1996-03-05 1999-03-25 Ekos Corporation Ultrasound assembly for use with light activated drugs
US5693789A (en) * 1996-04-10 1997-12-02 Abbott Laboratories Process for the preparation of a protoporphyrin
US5834503A (en) 1996-06-14 1998-11-10 Qlt Phototherapeutics, Inc. Methods to treat arterial plaque
US6043237A (en) * 1996-12-10 2000-03-28 Qlt Phototherapeutics, Inc. Use of photodynamic therapy for prevention of secondary cataracts
US6756396B1 (en) 1997-05-07 2004-06-29 Qlt Inc. Ethylene glycol esters as photoactive agents
IL132494A0 (en) * 1997-05-07 2001-03-19 Univ British Columbia A new class of benzoporphyrin derivative photoactive compounds
KR100397131B1 (ko) * 1997-05-07 2003-09-13 유니버시티 오브 브리티시 콜롬비아 광활성제로서 모노하이드로벤조포르피린 유도체의 에틸렌글리콜 에스테르
US5880145A (en) * 1997-05-07 1999-03-09 The University Of British Columbia Class of benzoporphyrin derivative photoactive compounds
AU8732598A (en) 1997-07-28 1999-02-16 Novartis Ag Device and method for irradiating a patient's eye for photodynamic therapy
CA2221912A1 (en) * 1997-11-21 1999-05-21 David Dolphin Photosensitizers with improved biodistribution and light-absorbing properties
US6316215B1 (en) 1999-12-27 2001-11-13 Edwin L. Adair Methods of cancer screening utilizing fluorescence detection techniques and selectable imager charge integration periods
DE69826521T2 (de) 1998-01-06 2005-09-29 Cerus Corp., Concord Verfahren zum quenchen von pathogen-inaktivatoren in biologischen materialien
US7157418B1 (en) 1998-07-22 2007-01-02 Osprey Pharmaceuticals, Ltd. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
US20030215421A1 (en) * 1999-07-21 2003-11-20 Mcdonald John R. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
AU4139600A (en) 1999-04-14 2000-11-14 University Of British Columbia, The 1,3-dipolar cycloadditions to polypyrrolic macrocycles
US20020022032A1 (en) * 1999-04-23 2002-02-21 Curry Patrick Mark Immuno-adjuvant PDT treatment of metastatic tumors
US7122568B1 (en) 1999-11-17 2006-10-17 Qlt, Inc. Use of low-dose PDT to inhibit restenosis
US6190877B1 (en) 1999-12-27 2001-02-20 Edwin L. Adair Method of cancer screening primarily utilizing non-invasive cell collection and fluorescence detection techniques
US6984498B2 (en) * 1999-12-27 2006-01-10 Adair Edwin L Method of cancer screening primarily utilizing non-invasive cell collection, fluorescence detection techniques, and radio tracing detection techniques
US6750037B2 (en) * 1999-12-27 2004-06-15 Edwin L. Adair Method of cancer screening primarily utilizing non-invasive cell collection, fluorescence detection techniques, and radio tracing detection techniques
WO2001074389A2 (en) * 2000-03-24 2001-10-11 Novartis Ag Improved treatment of neovascularization
CA2408332C (en) 2000-05-08 2011-02-15 The University Of British Columbia Supports for photosensitizer formulations
US6984395B2 (en) * 2001-04-11 2006-01-10 Qlt, Inc. Drug delivery system for hydrophobic drugs
CA2449828A1 (en) 2001-06-04 2003-01-16 The General Hospital Corporation Detection and therapy of vulnerable plaque with photodynamic compounds
WO2003037295A2 (en) * 2001-11-02 2003-05-08 The Governors Of The University Of Alberta Micelle compositions containing pegylated phospholipids and a photosensitizer
JP2005514346A (ja) * 2001-11-09 2005-05-19 キュー エル ティー インク． 光感作剤及び皮膚浸透エンハンサーを含有する組成物並びに光力学療法におけるそれらの使用
DE60307545T2 (de) * 2002-06-21 2007-10-04 Adair, Edwin L., Castle Pines Village Anwendung von Metalloporphyrinen zur Behandlung von Arteriosklerose
US20060258629A1 (en) * 2002-10-18 2006-11-16 Freeman William R Photodynamic therapy for ocular neovascularization
US20040220167A1 (en) * 2003-05-02 2004-11-04 Nasrollah Samiy Methods of treating neuralgic pain
CA2437638A1 (en) * 2003-08-20 2005-02-20 John Robert North Photodynamic therapy
CA2457214A1 (en) * 2004-02-06 2005-08-06 Qlt Inc. Photodynamic therapy for the treatment of acne
WO2006020979A2 (en) * 2004-08-13 2006-02-23 Yale University Factor vii conjugates for selectively treating neovascularization disorders
DK1838355T3 (da) 2004-10-29 2013-10-28 Cerus Corp Forbedrede quenching-fremgangsmåder til erytrocyt-inaktiveringsfremgangsmåde
AU2009233807B2 (en) 2008-04-09 2014-11-27 Cerus Corporation Improved quenching methods for red blood cell pathogen inactivation
US8829020B2 (en) 2009-07-16 2014-09-09 Mallinckrodt Llc Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
JP5964322B2 (ja) 2011-01-13 2016-08-03 キュー エル ティー インク．ＱＬＴ Ｉｎｃ． 光増感剤の局所送達用医薬組成物及びその使用
CN104379602B (zh) 2012-03-08 2017-05-03 哈洛齐梅公司 具有条件活性的抗表皮生长因子受体抗体及其使用方法
MX2015000429A (es) 2012-07-11 2015-07-14 Dermira Inc Composiciones farmaceuticas para el suministro topico de fotosesibilizadores y usos de los mismos.
EP3044236A2 (de) 2013-09-12 2016-07-20 Halozyme, Inc. Modifizierte anti-egfr-antikörper und verfahren zur verwendung davon
WO2017161206A1 (en) 2016-03-16 2017-09-21 Halozyme, Inc. Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
AU2018235945A1 (en) 2017-03-14 2019-10-17 Ohio State Innovation Foundation Methods and compositions related to a tissue factor-targeting IgG3 immunoconjugates
US12006356B2 (en) 2017-12-15 2024-06-11 Juno Therapeutics, Inc. Anti-CCT5 binding molecules and chimeric antigen receptors comprising the same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2951800A (en) * 1957-11-13 1960-09-06 Monsanto Chemicals Photoxidation processes utilizing improved catalysts
ATE53204T1 (de) * 1982-09-27 1990-06-15 Photofrin Medical Inc Gereinigte hematoporphyrinabkoemmlinge fuer diagnose und tumorbehandlung sowie verfahren.
US4649151A (en) * 1982-09-27 1987-03-10 Health Research, Inc. Drugs comprising porphyrins
US4675338A (en) * 1984-07-18 1987-06-23 Nippon Petrochemicals Co., Ltd. Tetrapyrrole therapeutic agents
AU583854B2 (en) * 1984-09-13 1989-05-11 Cytogen Corporation Antibody therapeutic agent conjugates
US4883790A (en) * 1987-01-20 1989-11-28 University Of British Columbia Wavelength-specific cytotoxic agents

Also Published As

Publication number Publication date
DE68924215D1 (de) 1995-10-19
EP0352076A2 (de) 1990-01-24
GR3017426T3 (en) 1995-12-31
NL300037I2 (nl) 2001-08-01
DE68924215T2 (de) 1996-02-15
ATE209650T1 (de) 2001-12-15
EP0641796B1 (de) 2001-11-28
AU638675B2 (en) 1993-07-08
ES2169060T3 (es) 2002-07-01
NL300037I1 (nl) 2001-03-01
DE68929351D1 (de) 2002-01-10
CA1339927C (en) 1998-06-23
ES2080745T3 (es) 1996-02-16
DE10199008I1 (de) 2003-06-12
EP0352076A3 (de) 1991-07-17
DE10199008I2 (de) 2004-10-14
EP0641796A1 (de) 1995-03-08
US4920143A (en) 1990-04-24
LU90718I2 (fr) 2001-03-01
EP0352076B1 (de) 1995-09-13
DE68929351T2 (de) 2002-05-08
AU3825889A (en) 1990-02-08

Similar Documents

Publication Publication Date Title
ATE127696T1 (de) Wellenlängenspeziphisches, cytotoxisches mittel.
Fingar et al. Drug and light dose dependence of photodynamic therapy: a study of tumor and normal tissue response
JP4662631B2 (ja) 光エネルギを用いた色素沈着組織の治療装置
EP0947222B1 (de) Verfahren zur Aktivierung von photoempfindlichen Mitteln
US5913884A (en) Inhibition of fibrosis by photodynamic therapy
BR9712599A (pt) Processos para o tratamento de um volume particular, de câncer e de um volume de tecido canceroso em tecido e para produzir pelo menos um agente molecular foto-ativo num volume particular de material e aparelhos para o tratamento de um volume particular de tecido de planta ou de animal e para a administração de um tratamento médico foto-dinâmico
HU220251B (hu) Fényérzékenyítő anyagok in vivo transzkután aktiválása a vérben
RU2006110554A (ru) Соединение для антимикробной фотодинамической терапии и способ применения
Biolo et al. Photodynamic therapy of B16 pigmented melanoma with liposome‐delivered Si (IV)‐naphthalocyanine
EP1120119A4 (de) Heilmittel für die photochemotherapie
Ash et al. Photodynamic therapy--achievements and prospects.
Razum et al. SnET2: clinical update
Petrozzi et al. Topical methoxsalen and blacklight in the treatment of psoriasis
WO1992000106A3 (en) Method of treatment and compositions therefore
PT1267931E (pt) Derivados de rodamina para o diagnostico e tratamento fotodinamicos
ATE87826T1 (de) Herstellung und verwendung von purpurinen, chlorinen und purpurin und chlorin enthaltenden zubereitungen.
AU3401093A (en) Therapeutic agent for threatened abortion
US20040176345A1 (en) Method for preventing or reducing collateral phototoxic damage to neighboring tissues during photodynamic therapy of a target tissue
Davis et al. Effects of photosensitizer (hematoporphyrin derivative‐HPD) and light dose on vascular targets in the albino mouse ear
Lubart et al. A light source for phototherapy
Tomio et al. Effect of hematoporphyrin and red light on AH-130 solid tumors in rats
RU2146159C1 (ru) Способ фотодинамической терапии злокачественных новообразований
Abramson et al. Clinical exacerbation of systemic lupus erythematosus after photodynamic therapy of laryngotracheal papillomatosis
US6586419B1 (en) Phototherapeutic inactivation of ocular viruses
Nyamekye Vascular and other non-tumour applications of photodynamic therapy